Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.48 |
| ▸ | PPIA | P62937 | 7/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007576 | 0.94 | MAPT (0.62) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL144326 | 0.80 | KMT2A (0.65) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL29273709 | 0.79 | MAPT (0.65) | KMT2AMEN1LMNAMAPTTSHR | |
| SCHEMBL1567605 | 0.78 | KMT2A (0.61) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL30735994 | 0.77 | KMT2A (0.75) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL29124181 | 0.77 | KMT2A (0.75) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL367886 | 0.77 | KMT2A (0.61) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL22873283 | 0.77 | KMT2A (0.61) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL5525117 | 0.76 | KMT2A (0.59) | KMT2AMEN1LMNAMAPTGAA | |
| Hydrochloric Acid SCHEMBL29012769 | 0.76 | KMT2A (0.59) | KMT2AMEN1LMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041674-B2 | Carbamic acid esters with anticholinergic activity | BOEHRINGER INGELHIEM PHARMA GMBH & CO. KG (DE) | 2006-05-09 | — | — | US | disclosed |
| US-20040132760-A1 | Carbamic acid esters with anticholinergic activity | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132760-A1 | Carbamic acid esters with anticholinergic activity | CHRM2, CHRM1, ACHE | KMT2A 1182/4885MEN1 1418/4885LMNA 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.